提高人工耳蜗项目中的肺炎球菌疫苗接种率:一项系统综述与Meta分析
该系统综述与Meta分析遵循PRISMA指南,检索PubMed、Scopus和CINAHL,纳入13项研究共12973名儿童和成人。基线PCV13和PPSV23接种率分别为53.45%(95% CI,37.02%-69.51%)和42.53%(95% CI,31.94%-53.48%)。质量改进干预后PPSV23接种率显著高于基线,达83.52%(95% CI,57.36%-98.46%)。
要点
- 人工耳蜗患者基线PCV13接种率为53.45%,PPSV23接种率为42.53%。
- 质量改进干预后PPSV23接种率显著高于基线,达83.52%。
- 干预后患者接受PPSV23接种的比值比为15.71(95% CI,4.32-57.20,P < .001)。
核心结论
- 人工耳蜗患者基线PCV13和PPSV23接种率变异大且低于当前推荐期望。
- 质量改进项目似乎能成功提高PPSV23接种依从性,但仍远未达到完全依从。
- 需要更严格的监测、监控和随访系统的进一步干预项目来提高人工耳蜗受者的PCV13和PPSV23接种依从性。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA指南,检索PubMed、Scopus和CINAHL。
- 共筛选641项研究,13项符合纳入标准。
- 纳入基线及质量改进干预前后肺炎球菌疫苗接种率的研究,共包含12973名儿童和成人。
主要发现
- 基线PCV13接种率为53.45%(95% CI,37.02%-69.51%),PPSV23接种率为42.53%(95% CI,31.94%-53.48%)。
- 儿童与成人之间PCV13和PPSV23基线接种率无统计学显著差异。
- 质量改进干预后PPSV23接种率显著高于基线,为83.52%(95% CI,57.36%-98.46%)。
- 干预后患者接受PPSV23接种的比值比为15.71(95% CI,4.32-57.20,P < .001),高于干预前。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review the literature on pneumococcal vaccination compliance rates among cochlear implant (CI) patients and to examine the utility of intervention programs on increasing vaccination rates. DATA SOURCES: PubMed, Scopus, and CINAHL. REVIEW METHODS: A systematic review was performed following PRISMA guidelines. Studies of pneumococcal vaccination rates at baseline and before and after the implementation of a quality improvement (QI) intervention were included. A total of 641 studies were screened, and 13 studies met inclusion criteria. Meta-analyses of pneumococcal vaccination rates pre- and post-QI intervention in CI patients were performed. RESULTS: A total of 12,973 children and adults were included. The baseline PCV13 and PPSV23 vaccination rates were 53.45% (95% CI, 37.02%-69.51%) and 42.53% (95% CI, 31.94%-53.48%), respectively. Comparing children and adults, PCV13 and PPSV23 baseline vaccination rates were not statistically significant. The PPSV23 vaccine rate after QI initiatives was significantly higher than the baseline rate at 83.52% (95% CI, 57.36%-98.46%). After these interventions, patients had a 15.71 (95% CI, 4.32-57.20, P < .001) increased odds of receiving PPSV23 vaccination compared to before QI implementation. CONCLUSIONS: The baseline rates of PCV13 and PPSV23 are highly variable and lower than expected, given current vaccination recommendations for CI patients. QI programs appear successful in increasing compliance rates with the PPSV23 vaccination; however, they are still far from full compliance. Further intervention programs with stricter surveillance, monitoring, and follow-up systems are needed to achieve improved compliance with the PCV13 and PPSV23 vaccination in CI recipients.
引用
- Britt AF, Poupore NS, Nguyen SA, et al. Improving Pneumococcal Vaccination Rates in Cochlear Implant Programs: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2023. PMID: 35852861. doi:10.1177/01945998221113310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。